News & Videos - FORMYCON AG - English

EQS-News: Formycon AG / Key word(s): Annual Report/Annual Results Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position 27.03.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // March 27, 2025 Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position Group revenue exceeds...

EQS-News: Formycon AG / Key word(s): Conference/Annual Report Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025 24.03.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // March 24, 2025 Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor...

EQS-News: Formycon AG / Key word(s): Product Launch FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union 03.03.2025 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // March 3, 2025 FYB202/Otulfi ® (u stekinumab-aauz ) , a biosimilar to Stelara ® , launched in the United States and the European Union FYB202/Otulfi ® is now commercially available in both subcutaneous and...

EQS-News: Formycon AG / Key word(s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // February 25, 2025 Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea ® , under the brand name AHZANTIVE ® FYB203 (aflibercept) approved in the UK...

EQS-News: Formycon AG / Key word(s): Scientific publication Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin 20.02.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // February 20, 2025 Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard, “Formycon”) will present an overview of...

EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon AG informs about recent developments in various biosimilar projects and invites to conference call 17.02.2025 / 09:27 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // February 17, 2025 Formycon AG informs about recent developments in various biosimilar projects and invites to conference call Formycon continues FYB206 development without Phase III trial and thus takes pioneering role among...

EQS-Ad-hoc: Formycon AG / Key word(s): Study/Statement Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201 17-Feb-2025 / 08:05 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Disclosure of inside information according to Article 17...

EQS-News: Formycon AG / Key word(s): Agreement Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region 05.02.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // February 05, 2025 Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea ® biosimilar FYB203/AHZANTIVE ® in the Asia-Pacific Region...

EQS-News: Formycon AG / Key word(s): Regulatory Approval Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // January 20, 2025 Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea ® , under the brand names AHZANTIVE ® and Baiama ® FYB203 (aflibercept) approved for the treatment of...

EQS-News: Formycon AG / Key word(s): Regulatory Approval Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // January 15, 2025 Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi ® (u stekinumab ), a biosimilar to Stelara ® Otulfi ® received MHRA approval for both subcutaneous and intravenous...

EQS-News: Formycon AG / Key word(s): Agreement Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel 13.01.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Presse Release // January 13, 2025 Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea ® / aflibercept) in major parts of Europe and Israel...

EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon included in TecDAX Index of Deutsche Börse 09.01.2025 / 15:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // January 9, 2025 Formycon included in TecDAX Index of Deutsche Börse Formycon to join the ranks of the 30 leading listed technology companies Uplisting to the Prime Standard, inclusion in the SDAX, and robust business development further enhance the stock’s appeal Entry into...

EQS-News: Formycon AG / Key word(s): Regulatory Approval Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 08.01.2025 / 14:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // January 8, 2025 Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi ® (u stekinumab ), a biosimilar to Stelara ® Otulfi ® approved by Health Canada for both...

EQS-News: Formycon AG / Key word(s): Agreement MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region 09.12.2024 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Presse Release // December 09, 2024 MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Planegg-Martinsried, Germany / Amman, Jodan – Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they...

EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon joins the SDAX of the German Stock Exchange 05.12.2024 / 12:55 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // December 5, 2024 Formycon joins the SDAX of the German Stock Exchange Formycon shares will be part of the DAX index family, ranking among the 70 largest German companies below the MDAX Enhanced share attractiveness following recent uplisting to the Prime Standard Formycon shares...

EQS-News: Formycon AG / Key word(s): 9 Month figures/Quarterly / Interim Statement Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes 28.11.2024 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // November 28, 2024 Formycon reports nine-month results for 2024 and continues growth trajectory with further operational success Excellent third quarter with product approvals for FYB202 in...

EQS-News: Formycon AG / Key word(s): 9 Month figures/Conference Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences 19.11.2024 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // November 19, 2024 Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences Planegg-Martinsried, Germany –...

EQS-News: Formycon AG / Key word(s): Statement/Regulatory Admission Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama® 18.11.2024 / 06:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // November 18, 2024 Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®...

EQS-Ad-hoc: Formycon AG / Key word(s): Statement/Regulatory Admission Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA 15-Nov-2024 / 18:18 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Disclosure of inside information according to Article 17 of the Regulation (EU) No...

EQS-News: Formycon AG / Key word(s): Personnel/Contract Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard 11.11.2024 / 17:41 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // November 11, 2024 Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard Dr. Stefan Glombitza has been...